consideration of these variables, no additional prognostic information was provided by considering the patient's functional status (ie, New York Heart Association [NYHA] class), right ventricular function (as assessed by tricuspid annular plane systolic excursion), routine laboratory data, or use of advanced therapy (ie, pulmonary arterial vasodilators). A 6-minute walk distance, excluded from the primary analysis because of missing data, remained predictive in an exploratory model.
What new information does this study provide? First, it suggests that the population with Eisenmenger syndrome seen in the setting of an adult CHD clinic may have a worse prognosis than previously recognized. Their results appear consistent with recent observations from the REVEAL registry (Registry to Evaluate Early and Long-term PAH Disease Management)-a longitudinal registry involving 55 pulmonary hypertension centers in the United States-which included 353 patients with CHD of whom 151 had Eisenmenger syndrome. 2 In the REVEAL registry, 4-year survival after enrollment was 77% for the cohort with Eisenmenger syndrome, which was similar to the survival of patients with repaired CHD, idiopathic PAH, and heritable PAH.
The REVEAL registry findings 2 and those by Kempny et al 1 appear to be incongruous with previous studies [3] [4] [5] showing a significantly better survival rate in patients with Eisenmenger syndrome than is expected in patients with idiopathic or heritable PAH. However, because the patients reported by Kempny et al 1 and in the REVEAL registry were enrolled from tertiary referral centers, it is not known whether they are truly representative of all patients with Eisenmenger syndrome as opposed to those with end-stage disease or symptoms (ie, those referred to tertiary centers for consideration of advanced therapy or heart-lung transplantation because of advanced disease). Accordingly, whether their poor outcome is representative of the population with Eisenmenger syndrome at large is unknown. Alternatively, the overly optimistic estimate of the long-term outcome of patients with Eisenmenger syndrome reported in previous studies [3] [4] [5] may be attributable to survivor treatment selection bias (ie, immortal time bias): to be enrolled, patients had to survive to an age where they could enter clinical follow-up at research institutions. 6 A long-term study that assesses survival of pediatric and adult patients from time of diagnosis rather than referral to a tertiary center would avoid ambiguities related to selection bias and provide a more meaningful assessment of prognosis of Eisenmenger syndrome.
The authors advocate that their 5 noninvasive predictors identify a high-risk subgroup of patients with Eisenmenger syndrome "that may benefit from advanced therapy or transplantation."
1 What therapy is available for such patients, and does such therapy affect survival? Furthermore, does the information in this study help inform the clinician when to initiate therapy?
Early treatment for Eisenmenger syndrome consisted of diuretics and anticoagulation, both of which proved deleterious in these patients. Supplemental oxygen and phlebotomy were also widely administered. However, studies showed that oxygen therapy has neither short-nor long-term beneficial effects, and repeated phlebotomies often lead to anemia, worsened exercise impairment, reduced quality of life, and increased risk of thromboembolic events. More recently, pulmonary vasoactive disease targeting therapies (ie, endothelin receptor antagonist, phosphodiesterase-5 inhibitor, or prostacyclin analog) have been administered. Multiple studies have shown these agents improve functional capacity, systemic arterial oxygen saturation, and pulmonary hemodynamics in patients with Eisenmenger syndrome. 7 However, whether pulmonary vasoactive therapies improve their survival is unclear. Two retrospective, observational studies 8, 9 reported survival benefit in patients with Eisenmenger syndrome receiving advanced therapy compared with advanced therapy-naïve patients. However, no prospective or randomized controlled studies have confirmed this benefit. Hence, no convincing data or consensus indicates that pharmacological therapy improves the survival of patients with Eisenmenger syndrome. Absent this consensus, the indication for initiation of pulmonary vasodilator therapy is worsening patient symptoms or functional status, neither of which, parenthetically, are predictors of the patient's survival.
To date, the only definitive treatment for Eisenmenger syndrome is lung transplantation (in combination with shunt closure) or heart-lung transplantation. Although patients with Eisenmenger syndrome may have a better prognosis after transplantation than patients with idiopathic PAH or other types of CHD, the paucity of donor organs and low survival rates after transplantation (ie, 80% at 30 days, 70% at 1 year, and 55% at 5 years) highlight the need for identification of patients most likely to benefit from transplantation or disease-modifying therapies.
Can the primary provider synthesize the information in the current study to decide when to refer the patient to transplantation? Unfortunately, although the investigators identified 5 predictors associated with death, their utility in selecting individuals suitable for transplantation is not described. What does the provider recommend to the patient with Eisenmenger syndrome with only 2, 3, or 4 predictors? Is the presence of 1 or multiple predictors sufficient to warrant referral to transplantation? If the presence of multiple predictors is required, then how many and which ones are important? Given the limited availability of donor organs and guarded outcome after lung transplantation, a quantitative risk assessment tool that calculates an individual patient with Eisenmenger syndrome's risk of death based on the 5 noninvasive predictors reported in this study would help providers determine the optimal time for referral to transplantation.
